GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034142 | Stomach | CAG | toll-like receptor 4 signaling pathway | 6/552 | 43/18723 | 1.54e-03 | 1.86e-02 | 6 |
GO:00508673 | Stomach | CAG | positive regulation of cell activation | 24/552 | 420/18723 | 1.64e-03 | 1.94e-02 | 24 |
GO:0034134 | Stomach | CAG | toll-like receptor 2 signaling pathway | 4/552 | 18/18723 | 1.65e-03 | 1.94e-02 | 4 |
GO:19004243 | Stomach | CAG | regulation of defense response to bacterium | 4/552 | 18/18723 | 1.65e-03 | 1.94e-02 | 4 |
GO:0062208 | Stomach | CAG | positive regulation of pattern recognition receptor signaling pathway | 6/552 | 44/18723 | 1.74e-03 | 2.02e-02 | 6 |
GO:00026902 | Stomach | CAG | positive regulation of leukocyte chemotaxis | 9/552 | 94/18723 | 1.82e-03 | 2.09e-02 | 9 |
GO:0051702 | Stomach | CAG | biological process involved in interaction with symbiont | 9/552 | 94/18723 | 1.82e-03 | 2.09e-02 | 9 |
GO:0002286 | Stomach | CAG | T cell activation involved in immune response | 10/552 | 114/18723 | 2.00e-03 | 2.29e-02 | 10 |
GO:0032757 | Stomach | CAG | positive regulation of interleukin-8 production | 7/552 | 62/18723 | 2.25e-03 | 2.50e-02 | 7 |
GO:000315831 | Stomach | CAG | endothelium development | 11/552 | 136/18723 | 2.33e-03 | 2.55e-02 | 11 |
GO:20003773 | Stomach | CAG | regulation of reactive oxygen species metabolic process | 12/552 | 157/18723 | 2.43e-03 | 2.61e-02 | 12 |
GO:0031343 | Stomach | CAG | positive regulation of cell killing | 7/552 | 63/18723 | 2.47e-03 | 2.62e-02 | 7 |
GO:00507143 | Stomach | CAG | positive regulation of protein secretion | 11/552 | 137/18723 | 2.47e-03 | 2.62e-02 | 11 |
GO:0001910 | Stomach | CAG | regulation of leukocyte mediated cytotoxicity | 8/552 | 82/18723 | 2.86e-03 | 2.92e-02 | 8 |
GO:0050921 | Stomach | CAG | positive regulation of chemotaxis | 11/552 | 141/18723 | 3.09e-03 | 3.04e-02 | 11 |
GO:0019221 | Stomach | CAG | cytokine-mediated signaling pathway | 25/552 | 472/18723 | 3.63e-03 | 3.38e-02 | 25 |
GO:0031349 | Stomach | CAG | positive regulation of defense response | 17/552 | 278/18723 | 3.81e-03 | 3.52e-02 | 17 |
GO:0034145 | Stomach | CAG | positive regulation of toll-like receptor 4 signaling pathway | 3/552 | 12/18723 | 4.60e-03 | 4.05e-02 | 3 |
GO:00326123 | Stomach | CAG | interleukin-1 production | 10/552 | 128/18723 | 4.64e-03 | 4.06e-02 | 10 |
GO:00326523 | Stomach | CAG | regulation of interleukin-1 production | 10/552 | 128/18723 | 4.64e-03 | 4.06e-02 | 10 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0513052 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2R | SNV | Missense_Mutation | | c.978N>G | p.Phe326Leu | p.F326L | P25116 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
F2R | SNV | Missense_Mutation | | c.253N>A | p.Pro85Thr | p.P85T | P25116 | protein_coding | tolerated(0.39) | benign(0.005) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2R | SNV | Missense_Mutation | novel | c.1106N>C | p.Leu369Pro | p.L369P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AO-A0JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
F2R | SNV | Missense_Mutation | | c.250N>T | p.Leu84Phe | p.L84F | P25116 | protein_coding | tolerated(0.69) | benign(0.063) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
F2R | SNV | Missense_Mutation | | c.238N>G | p.Leu80Val | p.L80V | P25116 | protein_coding | tolerated(0.55) | benign(0.039) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
F2R | insertion | Frame_Shift_Ins | novel | c.391_392insACACTACCAGGCTCTGCTCTGCTGTCTCTGAGTTGGTACTACTC | p.Met131AsnfsTer16 | p.M131Nfs*16 | P25116 | protein_coding | | | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
F2R | SNV | Missense_Mutation | | c.299N>C | p.Trp100Ser | p.W100S | P25116 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
F2R | SNV | Missense_Mutation | novel | c.727N>C | p.Thr243Pro | p.T243P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | novel | c.517N>A | p.Glu173Lys | p.E173K | P25116 | protein_coding | tolerated(0.57) | benign(0.096) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | | c.1210N>G | p.Met404Val | p.M404V | P25116 | protein_coding | tolerated(0.19) | benign(0) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | inhibitor | CHEMBL2013119 | RIGOSERTIB SODIUM | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | TYROSINE KINASE INHIBITOR | | 15383630 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | MORPHINE | MORPHINE | 12373743 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | ETHANOL | ALCOHOL | 16930224 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 405560412 | | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2103856 | ATOPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2107386 | VORAPAXAR SULFATE | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | WORTMANNIN | WORTMANNIN | 10318860,7559410,8955143 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 178100871 | VORAPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | agonist | 178100667 | | |